Functional Effector Threshold Linked to Response at Limited CAR-T Doses
Investigators deeply profiled anti-CD19 CAR-T products and leukapheresis starting material from the phase I/II HD-CAR-1 dose-escalation study. Among 28 treated patients, six achieved responses despite receiving low doses. These low-dose responders were enriched for…
